NCT03743636View on ClinicalTrials.gov

Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

May 23, 2023

Study Completion Date

May 23, 2023

Conditions
Peripheral Artery Disease
Interventions
DRUG

Nicotinamide riboside

Participants randomized to the NR + resveratrol arm or the NR + placebo arm of the study will receive 1,000 mg of NR daily for six months.

DRUG

Resveratrol

Participants randomized to the NR + resveratrol arm of the study will receive 125 mg of resveratrol daily for six months.

OTHER

Placebo

Participants randomized to the NR + placebo arm of the study will receiving placebo pills that are identical in appearance to resveratrol. Participants randomized to the placebo + placebo arm of the study will receive pills that are identical in appearance to NR and resveratrol. Participants will receive placebo pills daily for six months.

Trial Locations (1)

60611

Northwestern University, Chicago

All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

Northwestern University

OTHER

NCT03743636 - Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease | Biotech Hunter | Biotech Hunter